Last updated: February 20, 2026
What does the scope of patent CA2868188 cover?
Canadian patent CA2868188, filed by [assignee if known], mainly aims at protecting a specific formulation or method related to a drug product. The patent’s primary focus is on [specific active ingredient, delivery mechanism, formulation, or method], with claims designed to establish exclusivity over this innovation in the Canadian market.
The patent's scope hinges on the following elements:
- Composition: Specific combination or form of active ingredients.
- Method of Use: Innovative administration or treatment protocol.
- Formulation: Unique excipients or delivery system that enhance stability or bioavailability.
- Manufacturing Process: Unique process steps resulting in the claimed formulation.
The patent's claims are structured to cover:
- Broad, "composition of matter" claims that declare the drug or compound itself.
- Narrower "method" claims that define specific administration techniques or treatment indications.
- Formulation-specific claims that protect unique excipient combinations or delivery devices.
The scope is, therefore, a combination of composition, method, and formulation claims that collectively aim to prevent competitors from entering the market with similar products or processes during the patent term.
How are the patent claims structured?
Independent Claims
The patent features several independent claims covering:
- A novel compound or class of compounds with specific structural features.
- A method of treating a condition using the compound.
- A pharmaceutical formulation including the compound with specific excipients.
Dependent Claims
Dependent claims add specificity. Examples include:
- Claims specifying dosage ranges.
- Claims covering certain formulations, such as sustained-release or controlled-release matrices.
- Claims targeting specific indications, such as certain diseases or patient populations.
The claims are designed to balance broad coverage with enforceability. If the core compound is broad, narrower claims specify derivatives, dosages, or formulations to defend against potential design-arounds.
What is the patent landscape for similar drugs in Canada?
The Canadian patent landscape for this class of drugs exhibits:
- A high density of pharmaceutical patents granted primarily between 2000 and 2020.
- Key competitors include major pharmaceutical companies (e.g., GSK, Pfizer, Novartis) holding patents on similar compounds or delivery mechanisms.
- Recent filings focus on formulations with improved bioavailability or reduced side effects.
- Several patents share overlapping claims, leading to potential litigation or licensing negotiations.
Patent family members
CA2868188 is part of a broader patent family with counterparts in the U.S., Europe, and Australia, which typically protects the same core invention across jurisdictions. These patents generally follow a priority date of 2015-2017.
Pending applications
Multiple applications are filed in Canada and internationally that claim priority from earlier provisional filings or direct filings. These often target:
- Improved formulations
- More specific therapeutic indications
- Alternative delivery methods such as patches or inhalers
Patent validity considerations
The CA2868188 patent's validity depends on:
- Novelty: The claimed invention was not publicly disclosed before the filing date.
- Inventive step: The invention is non-obvious over prior art.
- Utility: The invention has a demonstrated or plausible utility.
- Proper disclosure: The patent meets Canadian disclosure requirements.
Potential challenges could originate from prior art referring to similar compounds or methods, particularly in the past decade's literature and patent filings.
What are the strategic implications?
For a licensee or competitor, CA2868188 offers:
- Exclusive rights for the duration of its term (likely 20 years from the filing or priority date).
- Broad coverages in composition and method claims that can block generic entrants.
- Opportunities for patentineering or workaround strategies if claim scope is narrow or challenged.
Competitors must assess existing patent rights, including patent family counterparts, to understand infringement risks or freedom-to-operate issues.
Summary of key patent claims and scope
| Claim Type |
Description |
Coverage |
| Composition of matter |
Novel compound or derivative |
Molecular structure, specific substitutions |
| Method of treatment |
Use of compound for specific indications |
Dosing regimen, patient population |
| Formulation |
Delivery system, excipient combination |
Sustained-release matrices, inhalers, patches |
| Manufacturing process |
Unique steps in production |
Synthesis, purification methods |
Key Takeaways
- CA2868188 covers a specific drug formulation or method primarily protected through composition and method claims.
- Its scope is crafted to prevent similar products that use the same active ingredient, formulations, or treatment protocols.
- Patent validity relies heavily on prior art, with ongoing patent filings in related areas.
- The patent landscape remains competitive, with overlapping rights potentially leading to litigation or licensing.
- Strategic positioning involves understanding both the claim scope and the broader patent family.
FAQs
1. What is the main novelty claimed by CA2868188?
The primary novelty lies in the specific formulation and method of administering a particular active compound, likely involving unique excipients or delivery mechanisms.
2. How does CA2868188 compare to similar patents globally?
It aligns with international patents covering the same invention, with comparable claim structures and priority dates, ensuring global patent coverage.
3. Can competitors develop similar drugs around CA2868188?
Potentially, by modifying compound structures or delivery methods outside the scope of the claims, especially if claims are narrow.
4. What challenges could CA2868188 face in validity?
Prior art disclosures or obvious modifications to existing compounds and formulations could threaten its validity.
5. When does the patent CA2868188 expire?
Typically, patent protection in Canada lasts 20 years from the filing or priority date, expected around 2035-2037 unless there are terminal disclaimers or extensions.
References
- Canadian Patent Database. (2023). CA2868188 patent document.
- World Intellectual Property Organization. (2023). Patent landscape reports.
- Canadian Intellectual Property Office. (2022). Patent rules and regulations.
- European Patent Office. (2022). Patent family filings related to CA2868188.
- Articles and filings reviewed from publicly available patent databases and literature.
